{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:58:09Z","timestamp":1785322689113,"version":"3.55.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["270650915"],"award-info":[{"award-number":["270650915"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["BH 162\/4-1"],"award-info":[{"award-number":["BH 162\/4-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GRK 2158"],"award-info":[{"award-number":["GRK 2158"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["528968169"],"award-info":[{"award-number":["528968169"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ejmech.2024.116447","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T22:48:12Z","timestamp":1714085292000},"page":"116447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Preferential HDAC6 inhibitors derived from HPOB exhibit synergistic antileukemia activity in combination with decitabine"],"prefix":"10.1016","volume":"272","author":[{"given":"Maik","family":"Tretbar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Schliehe-Diecks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"von Bredow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Roatsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Wey","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Kemkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melf","family":"S\u00f6nnichsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sch\u00f6ler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Borkhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanil","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9765-5975","authenticated-orcid":false,"given":"Finn K.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.ejmech.2024.116447_bib1","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1002\/anie.200461346","article-title":"Epigenetics - an Epicenter of gene regulation: histones and histone-Modifying enzymes","volume":"44","author":"Biel","year":"2005","journal-title":"Angew. Chem. Int. Ed."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116447_bib2","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.3390\/molecules20033898","article-title":"Histone deacetylase inhibitors in clinical studies as templates for New anticancer agents","volume":"20","author":"Mottamal","year":"2015","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.ejmech.2024.116447_bib3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2008.08.016","article-title":"HDAC family: what are the cancer relevant targets?","volume":"277","author":"Witt","year":"2009","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.ejmech.2024.116447_bib4","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3390\/cancers13040634","article-title":"Anticancer therapy with HDAC inhibitors: mechanism-based combination strategies and future perspectives","volume":"13","author":"Jenke","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ejmech.2024.116447_bib5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"21","key":"10.1016\/j.ejmech.2024.116447_bib6","doi-asserted-by":"crossref","first-page":"14787","DOI":"10.1021\/acs.jmedchem.3c01385","article-title":"Development of first-in-class dual Sirt2\/HDAC6 inhibitors as molecular tools for dual inhibition of tubulin deacetylation","volume":"66","author":"Sinatra","year":"2023","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.ejmech.2024.116447_bib7","doi-asserted-by":"crossref","first-page":"12460","DOI":"10.1021\/acs.jmedchem.0c00830","article-title":"Thirty years of HDAC inhibitors: 2020 insight and hindsight","volume":"63","author":"Ho","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116447_bib8","article-title":"FDA approves an HDAC inhibitor for Duchenne muscular dystrophy","author":"Mullard","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.116447_bib9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ejmech.2016.05.047","article-title":"Inside HDACs with more selective HDAC inhibitors","volume":"121","author":"Roche","year":"2016","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2024.116447_bib10","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/j.ejmech.2010.02.030","article-title":"Inside HDAC with HDAC inhibitors","volume":"45","author":"Bertrand","year":"2010","journal-title":"Eur. J. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2024.116447_bib11","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/cmdc.202000934","article-title":"Strategies to design selective histone deacetylase inhibitors","volume":"16","author":"Melesina","year":"2021","journal-title":"ChemMedChem"},{"issue":"11","key":"10.1016\/j.ejmech.2024.116447_bib25","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1021\/acs.orglett.8b01118","article-title":"Multicomponent synthesis and binding mode of imidazo[1,2-a]Pyridine-capped selective HDAC6 inhibitors","volume":"20","author":"Mackwitz","year":"2018","journal-title":"Org. Lett."},{"issue":"11","key":"10.1016\/j.ejmech.2024.116447_bib26","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/cmdc.202001011","article-title":"Oxa analogues of nexturastat A demonstrate improved HDAC6 selectivity and superior antileukaemia activity","volume":"16","author":"Pflieger","year":"2021","journal-title":"ChemMedChem"},{"issue":"7","key":"10.1016\/j.ejmech.2024.116447_bib27","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1039\/C8MD00454D","article-title":"Design, synthesis and biological evaluation of \u03b2-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity","volume":"10","author":"Re\u00dfing","year":"2019","journal-title":"MedChemComm"},{"issue":"24","key":"10.1016\/j.ejmech.2024.116447_bib12","doi-asserted-by":"crossref","first-page":"11260","DOI":"10.1021\/acs.jmedchem.9b01489","article-title":"Synthesis of peptoid-based class I-selective histone deacetylase inhibitors with chemosensitizing properties","volume":"62","author":"Krieger","year":"2019","journal-title":"J. Med. Chem."},{"issue":"22","key":"10.1016\/j.ejmech.2024.116447_bib13","doi-asserted-by":"crossref","first-page":"15457","DOI":"10.1021\/acs.jmedchem.2c01418","article-title":"Development of fluorinated peptoid-based histone deacetylase (HDAC) inhibitors for therapy-resistant acute leukemia","volume":"65","author":"Re\u00dfing","year":"2022","journal-title":"J. Med. Chem."},{"issue":"19","key":"10.1016\/j.ejmech.2024.116447_bib14","doi-asserted-by":"crossref","first-page":"13821","DOI":"10.1021\/acs.jmedchem.3c01345","article-title":"Difluoromethyl-1,3,4-Oxadiazoles are selective, mechanism-based, and essentially irreversible inhibitors of histone deacetylase 6","volume":"66","author":"K\u00f6nig","year":"2023","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116447_bib15","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/ijc.32169","article-title":"Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models","volume":"145","author":"Depetter","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"18","key":"10.1016\/j.ejmech.2024.116447_bib16","doi-asserted-by":"crossref","first-page":"10339","DOI":"10.1021\/acs.jmedchem.9b01888","article-title":"Multicomponent synthesis, binding mode, and structure\u2013activity relationship of selective histone deacetylase 6 (HDAC6) inhibitors with bifurcated capping groups","volume":"63","author":"Re\u00dfing","year":"2020","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116447_bib17","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/s41467-024-45440-7","article-title":"Targeting HDAC6 to treat heart failure with preserved ejection fraction in mice","volume":"15","author":"Ranjbarvaziri","year":"2024","journal-title":"Nat. Commun."},{"issue":"652","key":"10.1016\/j.ejmech.2024.116447_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.abl5654","article-title":"Phenotypic screening with deep learning identifies HDAC6 inhibitors as cardioprotective in a BAG3 mouse model of dilated cardiomyopathy","volume":"14","author":"Yang","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2024.116447_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.107072","article-title":"Groebke blackburn bienaym\u00e9-mediated multi-component synthesis of selective HDAC6 inhibitors with anti-inflammatory properties","volume":"143","author":"Kraft","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116447_bib20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s42255-021-00515-3","article-title":"Histone deacetylase 6 inhibition restores leptin sensitivity and reduces obesity","volume":"4","author":"\u00c7ak\u0131r","year":"2022","journal-title":"Nat. Metab."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116447_bib21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1021\/acs.jmedchem.9b00924","article-title":"Old but gold: tracking the new guise of histone deacetylase 6 (HDAC6) enzyme as a biomarker and therapeutic target in rare diseases","volume":"63","author":"Brindisi","year":"2020","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116447_bib22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/cmdc.201500486","article-title":"Why hydroxamates may not Be the best histone deacetylase inhibitors\u2014what some may have forgotten or would rather forget?","volume":"11","author":"Shen","year":"2016","journal-title":"ChemMedChem"},{"issue":"3","key":"10.1016\/j.ejmech.2024.116447_bib23","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1021\/acsptsci.4c00031","article-title":"2-(Difluoromethyl)-1,3,4-Oxadiazoles: the future of selective histone deacetylase 6 modulation?","volume":"7","author":"K\u00f6nig","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"12","key":"10.1016\/j.ejmech.2024.116447_bib24","doi-asserted-by":"crossref","first-page":"7698","DOI":"10.1021\/acs.jmedchem.3c00226","article-title":"The zinc-binding group effect: lessons from non-hydroxamic acid vorinostat analogs","volume":"66","author":"Geurs","year":"2023","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2024.116447_bib28","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nchembio.2140","article-title":"Structural insights into HDAC6 tubulin deacetylation and its selective inhibition","volume":"12","author":"Miyake","year":"2016","journal-title":"Nat. Chem. Biol."},{"issue":"9","key":"10.1016\/j.ejmech.2024.116447_bib29","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nchembio.2134","article-title":"Histone deacetylase 6 structure and molecular basis of catalysis and inhibition","volume":"12","author":"Hai","year":"2016","journal-title":"Nat. Chem. Biol."},{"issue":"24","key":"10.1016\/j.ejmech.2024.116447_bib30","doi-asserted-by":"crossref","first-page":"16860","DOI":"10.1021\/acs.jmedchem.2c01659","article-title":"Solid-phase synthesis of cereblon-recruiting selective histone deacetylase 6 degraders (HDAC6 PROTACs) with antileukemic activity","volume":"65","author":"Sinatra","year":"2022","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116447_bib31","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1021\/acschemneuro.5b00286","article-title":"Bicyclic-capped histone deacetylase 6 inhibitors with improved activity in a model of axonal charcot\u2013marie\u2013tooth disease","volume":"7","author":"Shen","year":"2016","journal-title":"ACS Chem. Neurosci."},{"issue":"11","key":"10.1016\/j.ejmech.2024.116447_bib32","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1021\/acsmedchemlett.1c00425","article-title":"Role of fluorination in the histone deacetylase 6 (HDAC6) selectivity of benzohydroxamate-based inhibitors","volume":"12","author":"Sandrone","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"issue":"17","key":"10.1016\/j.ejmech.2024.116447_bib33","doi-asserted-by":"crossref","first-page":"8054","DOI":"10.1021\/acs.jmedchem.8b01013","article-title":"Histone deacetylase 6-selective inhibitors and the influence of capping groups on hydroxamate-zinc denticity","volume":"61","author":"Porter","year":"2018","journal-title":"J. Med. Chem."},{"issue":"51","key":"10.1016\/j.ejmech.2024.116447_bib34","doi-asserted-by":"crossref","first-page":"13459","DOI":"10.1073\/pnas.1718823114","article-title":"Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors","volume":"114","author":"Porter","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"20","key":"10.1016\/j.ejmech.2024.116447_bib35","doi-asserted-by":"crossref","first-page":"5506","DOI":"10.1182\/blood-2011-02-336891","article-title":"HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL","volume":"118","author":"Kalac","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ejmech.2024.116447_bib36","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/s41375-018-0293-8","article-title":"Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation","volume":"33","author":"Blagitko-Dorfs","year":"2019","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.ejmech.2024.116447_bib43","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","article-title":"SynergyFinder: a web application for analyzing drug combination dose\u2013response matrix data","volume":"33","author":"Ianevski","year":"2017","journal-title":"Bioinformatics"},{"issue":"1","key":"10.1016\/j.ejmech.2024.116447_bib37","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1038\/s41598-020-60409-4","article-title":"Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer","volume":"10","author":"Moufarrij","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116447_bib38","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1868-7083-6-19","article-title":"Epigenetic therapy of acute myeloid leukemia using 5-Aza-2\u2019-Deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation","volume":"6","author":"Momparler","year":"2014","journal-title":"Clin. Epigenetics"},{"issue":"31","key":"10.1016\/j.ejmech.2024.116447_bib39","doi-asserted-by":"crossref","first-page":"51429","DOI":"10.18632\/oncotarget.18009","article-title":"Decitabine-vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for Novel triple therapy","volume":"8","author":"Young","year":"2017","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.ejmech.2024.116447_bib40","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.3109\/10428194.2015.1018248","article-title":"A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia","volume":"56","author":"How","year":"2015","journal-title":"Leuk. Lymphoma"},{"issue":"2","key":"10.1016\/j.ejmech.2024.116447_bib41","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bjh.13016","article-title":"A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome","volume":"167","author":"Kirschbaum","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116447_bib42","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/561","article-title":"Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription","volume":"19","author":"Jones","year":"1998","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2024.116447_bib44","article-title":"Compounds as S-nitrosoglutathione reductase inhibitors","author":"Sun","year":"2012","journal-title":"WO 2012\/170371 A1"},{"key":"10.1016\/j.ejmech.2024.116447_bib45","series-title":"Molecular Operating Environment (MOE)","year":"2022"},{"issue":"3","key":"10.1016\/j.ejmech.2024.116447_bib46","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1006\/jmbi.1996.0897","article-title":"Development and validation of a genetic algorithm for flexible docking 1 1Edited","volume":"267","author":"Jones","year":"1997","journal-title":"J. Mol. Biol."},{"issue":"19","key":"10.1016\/j.ejmech.2024.116447_bib47","doi-asserted-by":"crossref","first-page":"14620","DOI":"10.1021\/acs.jmedchem.1c01119","article-title":"4-Acyl pyrrole capped HDAC inhibitors: a new scaffold for hybrid inhibitors of BET proteins and histone deacetylases as antileukemia drug Leads","volume":"64","author":"Sch\u00e4ker-H\u00fcbner","year":"2021","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116447_bib48","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3390\/ph16030356","article-title":"Photocaged histone deacetylase inhibitors as Prodrugs in targeted cancer Therapy","volume":"16","author":"Kraft","year":"2023","journal-title":"Pharmaceuticals"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424003271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424003271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:06:04Z","timestamp":1777529164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424003271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":48,"alternative-id":["S0223523424003271"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116447","relation":{"has-preprint":[{"id-type":"doi","id":"10.26434\/chemrxiv-2024-flvmf-v2","asserted-by":"object"},{"id-type":"doi","id":"10.26434\/chemrxiv-2024-flvmf","asserted-by":"object"}]},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preferential HDAC6 inhibitors derived from HPOB exhibit synergistic antileukemia activity in combination with decitabine","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116447","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116447"}}